{
  "trial_id": "NCT00483223",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Histologically confirmed invasive breast cancer",
      "label": "met",
      "evidence": "physical examination or radiological study"
    },
    {
      "criterion": "Stage IV disease, according to AJCC 6th edition",
      "label": "met",
      "evidence": "biopsy proven or with unequivocal evidence of metastatic disease"
    },
    {
      "criterion": "ER-, PGR- and HER2-negative",
      "label": "met",
      "evidence": "tumor characteristics"
    },
    {
      "criterion": "18 years of age or older",
      "label": "met",
      "evidence": "patient's age"
    },
    {
      "criterion": "Paraffin tissue block is required from the primary tumor tissue or from diagnostic metastatic biopsy at time of relapse",
      "label": "met",
      "evidence": "tumor characteristics and treatment history"
    },
    {
      "criterion": "Measurable disease by RECIST",
      "label": "met",
      "evidence": "tumor characteristics and imaging studies"
    },
    {
      "criterion": "Performance status of 0,1 or 2 by ECOG criteria (Eastern Cooperative Oncology Group)",
      "label": "met",
      "evidence": "patient's performance status"
    },
    {
      "criterion": "Life expectancy greater than 12 weeks",
      "label": "met",
      "evidence": "patient's overall health and treatment plan"
    },
    {
      "criterion": "Normal organ and bone marrow function documented within 14 days prior to enrollment as defined by the protocol",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "18 years of age or older",
      "label": "met",
      "evidence": "patient's age"
    },
    {
      "criterion": "Measurable disease by RECIST",
      "label": "met",
      "evidence": "tumor characteristics and imaging studies"
    },
    {
      "criterion": "Performance status of 0,1 or 2 by ECOG criteria (Eastern Cooperative Oncology Group)",
      "label": "met",
      "evidence": "patient's performance status"
    }
  ],
  "exclusion": [
    {
      "criterion": "More than 1 prior chemotherapy for the treatment of recurrent or metastatic breast cancer",
      "label": "not_met",
      "evidence": ""
    },
    {
      "criterion": "Prior treatment with cisplatin, carboplatin, or other platinum chemotherapy agents",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Active brain metastases or unevaluated neurological symptoms suggestive of brain metastases",
      "label": "not_met",
      "evidence": ""
    },
    {
      "criterion": "Intercurrent illness or other major medical condition or comorbid condition that might affect study participation",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Significant history of uncontrolled cardiac disease such as uncontrolled hypertension, unstable angina, recent myocardial infarction, uncontrolled congestive heart failure, cardiomyopathy either symptomatic or asymptomatic but with decreased ejection fraction <45%",
      "label": "not_met",
      "evidence": ""
    },
    {
      "criterion": "Renal dysfunction for which cisplatin dose would either require dose modification or would be considered unsafe",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Pregnant or nursing women",
      "label": "not_met",
      "evidence": ""
    },
    {
      "criterion": "History or other malignancy that was not treated with curative intent",
      "label": "unknown",
      "evidence": ""
    }
  ],
  "notes": "45-year-old postmenopausal woman with cytologically confirmed breast cancer, HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes.",
  "_meta": {
    "topic_id": "61",
    "trial_id": "NCT00483223",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}